RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for … Read more
Market Cap & Net Worth: RemeGen Co. Ltd (REGMF)
RemeGen Co. Ltd (PINK:REGMF) has a market capitalization of $312.87 Million ($312.87 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #10252 globally and #4786 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RemeGen Co. Ltd's stock price $1.50 by its total outstanding shares 208581239 (208.58 Million).
RemeGen Co. Ltd Market Cap History: 2021 to 2025
RemeGen Co. Ltd's market capitalization history from 2021 to 2025. Data shows change from $3.26 Billion to $312.87 Million (-42.75% CAGR).
RemeGen Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RemeGen Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.18x
RemeGen Co. Ltd's market cap is 0.18 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.26 Billion | $1.42 Billion | $276.26 Million | 2.29x | 11.80x |
| 2022 | $2.92 Billion | $767.77 Million | -$998.83 Million | 3.80x | N/A |
| 2023 | $855.18 Million | $1.08 Billion | -$1.51 Billion | 0.79x | N/A |
| 2024 | $312.87 Million | $1.71 Billion | -$1.47 Billion | 0.18x | N/A |
Competitor Companies of REGMF by Market Capitalization
Companies near RemeGen Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to RemeGen Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
RemeGen Co. Ltd Historical Marketcap From 2021 to 2025
Between 2021 and today, RemeGen Co. Ltd's market cap moved from $3.26 Billion to $ 312.87 Million, with a yearly change of -42.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $312.87 Million | 0.00% |
| 2024 | $312.87 Million | -63.41% |
| 2023 | $855.18 Million | -70.71% |
| 2022 | $2.92 Billion | -10.43% |
| 2021 | $3.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of RemeGen Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $312.87 Million USD |
| MoneyControl | $312.87 Million USD |
| MarketWatch | $312.87 Million USD |
| marketcap.company | $312.87 Million USD |
| Reuters | $312.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.